- Home
- GNLX vs PALI Comparison
GNLX vs PALI Comparison
Compare GNLX & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.44
HOLD
Current Price
$1.78
Company Overview
Basic Information| Metric | GNLX | PALI |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 240.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNLX | PALI |
|---|---|---|
| Price | $2.44 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $19.75 | $15.00 |
| AVG Volume (30 Days) | 265.8K | ★ 5.1M |
| Earning Date | 03-27-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $0.53 |
| 52 Week High | $8.54 | $2.64 |
Technical Indicators
Market Signals| Indicator | GNLX | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 49.12 |
| Support Level | $2.31 | $1.48 |
| Resistance Level | $2.55 | $1.68 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 15.26 | 58.82 |
Price Performance
Historical Comparison GNLX
PALI
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.